Paggiaro, Pierluigi; Garcia, Gabriel; Roche, Nicolas; Verma, Manish; Plank, Maximilian; Oosterholt, Sean; Duong, Janna K; ... Della Pasqua, Oscar; + view all Paggiaro, Pierluigi; Garcia, Gabriel; Roche, Nicolas; Verma, Manish; Plank, Maximilian; Oosterholt, Sean; Duong, Janna K; Majumdar, Anurita; Della Pasqua, Oscar; - view fewer (2024) Baseline Characteristics and Maintenance Therapy Choice on Symptom Control, Reliever Use, Exacerbation Risk in Moderate–Severe Asthma: A Clinical Modelling and Simulation Study. Advances in Therapy , 41 pp. 4065-4088. 10.1007/s12325-024-02962-2.

Preview	Text (Published Version) Della Pasqua8_Vor_ Baseline characteristics and maintenance therapy choice on symptom_s12325-024-02962-2.pdf Download (6MB) | Preview
Preview	Text (Supplementary material 1) Suppl 1 - MASTER7_Supplementary Material ACQ_29July24.pdf - Accepted Version Download (3MB) | Preview
Preview	Text (Supplementary material 2) Suppl 2 - MASTER7_Supplementary Material Reliever_29JUL24.pdf - Accepted Version Download (2MB) | Preview
Preview	Text (Supplementary material 3) Suppl 3 - MASTER7_Supplementary Material TTE_29JULY24.pdf - Accepted Version Download (4MB) | Preview
Preview	Text (Supplementary material 4) Suppl 4 - MASTER7_Supplementary Material SIM_29JULY24.pdf - Accepted Version Download (5MB) | Preview

Abstract

Introduction: Although some factors associated with asthma symptom deterioration and risk of exacerbation have been identified, these are not yet fully characterised. We conducted a clinical modelling and simulation study to understand baseline factors affecting symptom control, reliever use and exacerbation risk in patients with moderate–severe asthma during follow-up on regularly dosed inhaled corticosteroid (ICS) monotherapy, or ICS/long-acting beta2-agonist (LABA) combination therapy.// Methods: Individual patient data from randomised clinical trials (undertaken between 2001 and 2019) were used to model the time course of symptoms (n = 7593), patterns of reliever medication use (n = 3768) and time-to-first exacerbation (n = 6763), considering patient-specific and extrinsic factors, including treatment. Model validation used standard graphical and statistical criteria. Change in symptom control scores (Asthma Control Questionnaire 5 [ACQ-5]), reduction in reliever use and annualised exacerbation rate were then simulated in patient cohorts with different baseline characteristics and treatment settings.// Results: Being a smoker, having higher baseline ACQ-5 and body mass index affected symptom control scores, reliever use and exacerbation risk (p < 0.01). In addition, low forced expiratory volume in 1 s percent predicted, female sex, season and previous exacerbations were found to contribute to a further increase in exacerbation risk (p < 0.01), whereas long asthma history was associated with more frequent reliever use (p < 0.01). These effects were independent from the underlying maintenance therapy. In different scenarios, fluticasone furoate (FF)/vilanterol was associated with greater reductions in reliever use and exacerbation rates compared with FF or fluticasone propionate (FP) alone or budesonide/formoterol, independently from other factors (p < 0.01).// Conclusions: This study provided further insight into the effects of individual baseline characteristics on treatment response and highlighted significant differences in the performance of ICS/LABA combination therapy on symptom control, reliever use and exacerbation risk. These factors should be incorporated into clinical practice as the basis for tailored management of patients with moderate–severe asthma.

Download activity - last month

Export as JSONCSVXML

Download activity - last 12 months

Export as JSONXMLCSV

Downloads by country - last 12 months

Export as CSVXMLJSON

Archive Staff Only

View Item